title: [Arterial infusion of SMANCS-Lipiodol for advanced hepatocellular carcinoma].
abstract: Twenty-four patients were treated with arterial infusion of SMANCS dissolved in Lipiodol. Twenty of these patients had HCC with the main trunks of portal vein occluded by tumor, and four patients had severe cirrhosis and multiple HCC. The actual dose of SMANCS administered each patient ranged from 4 to 6 mg. Side effects occurred in 50%. Severe side effects such as shock and shivering-chilliness were observed in 18%. The differences between the values of hepatic functional serum indexes obtained before and after treatment with SMANCS were small and transient. With regard to the therapeutic response of the arterial infusion of SMANCS, the mean survival time was approximately 2.8 months. It was suggested that the more effective administration of SMANCS was combination of the arterial infusion of SMANCS-Lipiodol with TAE at the level of the right hepatic artery of left hepatic artery for multiple HCC.
authors.affiliation: Dept. of Radiology, Hyogo College of Medicine.
authors.forename: K
authors.initials: K
authors.lastname: Miura
authors.forename: N
authors.initials: N
authors.lastname: Nakao
authors.forename: A
authors.initials: A
authors.lastname: Yoshimoto
authors.forename: T
authors.initials: T
authors.lastname: Yamano
authors.forename: J
authors.initials: J
authors.lastname: Inoue
authors.forename: Y
authors.initials: Y
authors.lastname: Takayasu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000503:physiopathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage* / Q000009:adverse effects; D008099:Liver / Q000503:physiopathology; D008113:Liver Neoplasms / Q000503:physiopathology / Q000628:therapy*; D008299:Maleic Anhydrides / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage* / Q000009:adverse effects; D009353:Zinostatin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D007459:Iodized Oil; D009353:Zinostatin